The publication describes the discovery of a novel series of Imidazopyrazine derivatives by IRBM’s drug discovery team. This novel series of SHP2 allosteric inhibitors, having an imidazopyrazine 6,5-fused heterocyclic system as central scaffold, showed an excellent potency in enzyme and cellular assays.
IRBM publishes in J. Peptide Science on methods to study catabolism, key to designing more stable peptides
IRBM used liquid chromatography-high resolution mass spectrometry to explore different methods for the study of catabolism (breakdown) which is a key driver in the design of more stable peptides.This is challenging to do analytically in a way that captures the highly heterogeneous products generated from catabolism and provide a full picture of what is happening. The art of it is having the right protein precipitation (PP) and solid-phase extraction (SPE) protocols. The paper gives insights on selecting optimal PP & SPE extraction conditions for the study of peptide catabolism, based on examining four model peptides representative of different structural classes: somatostatin, GLP‐2, human insulin and liraglutide.
Related Posts
